At present, digoxin should not be recommended for the treatment of patients with mild-to-moderate diastolic HF with preserved LVEF of greater than 45% in sinus rhythm This was an ancillary study ...

Digoxin oral tablet is available as both a generic and brand-name drug. Brand name: Lanoxin. Digoxin is also available as an oral solution. Digoxin oral tablet is used to treat atrial fibrillation, ...

Digoxin is available in oral form. Your body absorbs it, and it then travels to your body’s tissues, especially your heart, kidney, and liver. Your doctor performs digoxin testing to make sure that ...

What is digoxin used for? Digoxin is commonly used for the following conditions. Digoxin may also be used for other conditions as determined by your healthcare provider. How does digoxin work ...

Prognosis in Patients With Sentinel Node–Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and Dewar Topography Criteria Two thousand one hundred forty-four of 104,648 women ...

A randomized trial shows no significant difference in the primary endpoint of quality of life at 6 months between treatment with digoxin vs the beta-blocker bisoprolol (Zebeta) in patients with atrial ...

Are you taking Digoxin? Are you aware of the dangers of combining Digoxin with certain foods, herbs, or alcohol? Drug-food-interactions are seldom discussed but can lead to undesirable side effects ...

Medical topics worthy of writing about transcend the details of the drug or device and implicate a broader lesson. The medical establishment's turn against digoxin perfectly illustrates this duality.

This is a preview. Log in through your library . Abstract Purpose Digoxin affects several cellular pathways involved in tumorigenesis. We sought to determine the association between digoxin use and ...

Add Yahoo as a preferred source to see more of our stories on Google. A monitor is seen during a heart catheterization. A prescription medication to treat congestive heart failure is being recalled in ...

Andrew McLachlan is the Program Director for the NHMRC Centre for Resarch Excellence in Medicines and Ageing. He was an investigator on the PACE trial (ACTRN 12609000966291) which was an ...